ArticleJournal of family medicine and primary care2021
COVID-19 treatment in children: A systematic review and meta-analysis.
Article in Journal of family medicine and primary care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Remdesivir for the treatment of children hospitalized with COVID-19: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Multisystem Inflammatory Syndrome Associated With COVID-19 in Children (MIS-C): A Systematic Review of Studies From India.Indian pediatrics · 2022Pooled it
- Pediatric Use of Off-Label Medicines and Nonevidence-Based Supplements for COVID-19: Findings From the 2015 Pelotas Birth Cohort Study (Brazil).Pharmacoepidemiology and drug safety · 2026Article
- Biochemical simulation of mutation synthesis and repair during SARS-CoV-2 RNA polymerization.Virology · 2024Article
- Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.Italian journal of pediatrics · 2024Article
- New insight into the intravenous immunoglobulin treatment in Multisystem Inflammatory Syndrome in children and adults.Italian journal of pediatrics · 2024Review
- Therapeutic interventions and the length of hospital stay for pediatric patients with COVID-19: a multicenter cohort study.Scientific reports · 2023Article
- COVID-19 and Related Vaccinations in Children: Pathogenic Aspects of Oral Lesions.Children (Basel, Switzerland) · 2023Review
- Oral Candidiasis in Adult and Pediatric Patients with COVID-19.Biomedicines · 2023Article
- Article
- Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity.BMJ paediatrics open · 2022Article
- COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines.Children (Basel, Switzerland) · 2022Review
- Medication use in pediatric patients with covid-19 hospitalized in a referral hospital in Lima, Peru, 2020 - 2022.Revista peruana de medicina experimental y salud publicaArticle
- Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExact information about the efficacy of various medications proposed by regulatory bodies in children with COVID-19 is limited due to the lack of controlled trials in the existing literature.
methodsDifferent electronic databases (MEDLINE, EMBASE, Web of Science, COCHRANE CENTRAL, LitCovid, medRxiv, and bioRxiv) were searched for articles describing the management of COVID-19 cases in children with 18 shortlisted medications. Prospective/retrospective studies/case series (with at least 20 cases) reporting COVID-19 in patients aged ≤14 years were searched to collect information regarding clinical details and severity of participants, medications used, and outcome. The pooled estimate of these parameters across studies was performed using a random-effect or fixed-effect meta-analysis depending on the degree of heterogeneity.
resultsFrom a total of 5794 records, 97 studies/case series (8243 patients) fulfilled the eligibility criteria and were included in this systematic review. A total of 21% children received at least one medication specifically used for COVID-19. While antivirals were used in 15.3% of children, remedesivir was the most commonly used antiviral drug in 6.2% of included children without many reports of serious adverse effects. There was a more prevalent use of anti-inflammatory medications including corticosteroids (27.8%,
conclusionAmong pharmacological modalities, anti-inflammatory agents like corticosteroids and antivirals like remdesivir have the most promising evidence for severe cases of pediatric COVID-19. Intravenous immunoglobulin and other anti-inflammatory/immunomodulatory agents like anakinra, aspirin, and anticoagulants have important therapeutic role in cases with MIS-C. Most of the mild cases recover with conservative treatment only.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.